Research Priorities

A running punch list of studies/guidelines worth ingesting next, generated 2026-08-19 by sweeping the “Open items / gaps” section of every wiki page. Organized by how actionable each gap is, not by folder. Check items off (and link the new source page) as they’re ingested; re-sweep periodically as new gaps get flagged during ingests and lints.

High-priority named studies

These resolve a specific gap the wiki has already identified — highest value per ingest.

Rectal cancer / TNT (see Rectal Cancer, Total Neoadjuvant Therapy (TNT))

• POLISH II — ingested 2026-08-20, see Ciseł 2019 - POLISH II Long-Term Results. Result: a genuinely neutral trial (no efficacy benefit or locoregional trade-off in either direction).
• RAPIDO 5-year follow-up (Dijkstra et al., Ann Surg 2023) — ingested 2026-08-20, see Dijkstra 2023 - RAPIDO 5-Year Locoregional Failure. Resolved the previously-unresolved locoregional-recurrence disagreement: RAPIDO’s local-control trade-off is now confirmed statistically significant (10.2% vs 6.1% LRR, P=0.027) and RAPIDO-specific — not replicated in PRODIGE 23, STELLAR, or POLISH II.
• IDEA duration collaboration — currently only textbook-sourced (Sabiston), not independently ingested.
• JANUS and NORAD01-GRECCAR16 protocols ingested 2026-08-20 — see Alvarez 2024 - JANUS Trial Protocol and Brouquet 2020 - GRECCAR16 Trial Protocol. Both still accruing/awaiting results — re-check for published outcomes in a future ingest.
• ACO/ARO/AIO-18, GRECCAR 14 — still referenced only secondhand (Boublikova review and PRODIGE 23’s discussion, respectively); protocols or results not yet ingested.
• OPRA trial (Garcia-Aguilar et al.) — referenced by name (not ingested) in Total Neoadjuvant Therapy (TNT), Alvarez 2024 - JANUS Trial Protocol, and Boublikova 2023 - TNT in Rectal Cancer Review as the key primary data point for the pCR/non-operative-management-success dissociation — load-bearing to the NOM discussion but only known secondhand. Flagged in the 2026-08-20 lint pass.

Neuroendocrine tumors (see Small Bowel Neuroendocrine Tumors (NETs))

• TELESTAR — telotristat-etiprate for carcinoid syndrome; currently textbook-only (35% reduction in daily bowel movements figure is unverified against primary data).
• RADIANT-2 — everolimus + octreotide in functioning NETs (distinct from the already-ingested RADIANT-4).

Diverticulitis (see Diverticulitis, SCANDIV Trial)

• DILALA — referenced repeatedly in SCANDIV’s and the Ladies trial’s own discussions, never independently ingested.
• LapLAND — same as above.
• SCANDIV 90-day report (Schultz 2015, JAMA) and 1-year report (Schultz 2017, BJS) — to see how the recurrence/reoperation gap develops over time relative to the 5-year data already in.

Peritoneal disease / HIPEC (see Cytoreductive Surgery and HIPEC)

• PRODIGE 7 (primary publication) — ingested 2026-08-20, see Quénet 2021 - PRODIGE 7 Trial. Confirmed no OS/RFS benefit from adding HIPEC to CRS, plus new detail (significantly more morbidity at 60 days with HIPEC) not previously in the wiki.
• COLOPEC — still only known via a secondary review’s summary.
• Mitomycin-vs-oxaliplatin RCT — same.

Small bowel adenocarcinoma (see Small Bowel Adenocarcinoma)

• BALLAD — no standard adjuvant protocol is documented pending this.

IBD (see Crohn Disease, Ulcerative Colitis)

• Crohn’s-specific ACG guideline — only the UC-specific ACG 2025 guideline is ingested so far (BSG 2025 - IBD Guidelines (Adults) covers Crohn’s broadly, but not to ACG’s depth).
• Crohn’s-specific AGA guideline — same gap, AGA side.
• VARSITY trial (vedolizumab vs. adalimumab head-to-head) — the one real head-to-head data point both ACG 2025 - Ulcerative Colitis Guideline and AGA 2024 - Moderate-to-Severe UC Pharmacotherapy Guideline lean on for UC drug positioning, but known to the wiki only via the two guidelines’ paraphrase, never as its own primary source. Flagged in the 2026-08-20 lint pass.

Infectious colitis (see Infectious Colitis)

• Current IDSA/SHEA C. diff guideline — the antibiotic table in the wiki is currently just the textbook’s paraphrase of it.

Condition pages with zero primary literature

Entire pages still built solely from the Sabiston textbook chapters — good candidates for a ground-up strengthening rather than chasing one citation.

• Appendiceal Neoplasms — MAN/PMP, GCA, colonic-type, and signet-ring subtypes (the NET systemic-therapy piece was updated in the 2026-08-19 lint pass; the other four subtypes are still textbook-only).
• Gastrointestinal Stromal Tumors (GIST) — imatinib RCTs, risk-stratification validation.
• Short Bowel Syndrome — teduglutide trials, growth hormone meta-analysis, intestinal transplant survival data.
• Radiation Enteritis — the glutamine RCT and other prevention agents cited.
• Enterocutaneous Fistula — octreotide RCTs, fistuloclysis technique, spontaneous-closure retrospective data.
• Meckel Diverticulum — the incidental-finding malignancy-incidence controversy is explicitly flagged as a good candidate if Stephen wants to dig deeper.
• Rectal Prolapse (Procidentia) / Rectocele / Solitary Rectal Ulcer Syndrome (SRUS) — comparative repair-technique outcomes across all three.
• Hereditary CRC syndromes — Lynch Syndrome, Familial Adenomatous Polyposis (FAP), Hamartomatous Polyposis Syndromes — genetic/chemoprevention trial data, extended vs. limited colectomy RCT data for Lynch.

Contested clinical questions worth a dedicated source

Genuinely active debates where the wiki currently describes both sides without comparative data.

• Stenting-as-bridge-to-surgery vs. straight-to-surgery for obstructing colon cancer — flagged independently on both Large Bowel Obstruction and Obstructing Colon Cancer.
• Antibiotics vs. no antibiotics for uncomplicated diverticulitis — see Diverticulitis.
• taTME long-term oncologic outcomes vs. conventional TME — see Total Mesorectal Excision (TME) & Sphincter-Sparing Resection.

Maintenance

• This list isn’t exhaustive — it’s a sweep of explicit “Open items / gaps” notes, not a literature search. Smaller, page-specific gaps (e.g. LARS score validation, CME with central vascular ligation, malrotation/volvulus) remain on their respective pages’ own Open items sections and aren’t duplicated here.
• When a listed study is ingested, check it off here, link the new source page, and update the originating page’s Open items note so the two don’t drift out of sync.